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Abstract
Over-expression of alpha-phenol-soluble modulins (PSMs) results in high virulence of community-associated methicillin-resistant
Staphylococcus aureus (MRSA). The psm-mec gene, located in the mobile genetic element SCCmec-II, suppresses PSMas production. Fifty-two
patients with MRSA bacteraemia were enrolled. MRSA isolates were evaluated with regard to the psm-mec gene sequence, bacterial virulence,
and the minimum inhibitory concentration (MIC) of vancomycin and teicoplanin. Fifty-one MRSA isolates were classiﬁed as SCCmec-II, and 10
had one point mutation in the psm-mec promoter. We compared clinical characteristics and outcomes between mutant MRSA and wild-type
MRSA. Production of PSMa3 in mutant MRSAwas signiﬁcantly increased, but bioﬁlm formation was suppressed.Wild-typeMRSA causedmore
catheter-related bloodstream infections (30/41 vs. 3/10, p 0.0028), whereas mutant MRSA formed more deep abscesses (4/10 vs. 3/41,
p 0.035). Bacteraemia caused by mutant MRSA was associated with reduced 30-day mortality (1/10 vs. 13/41, p 0.25), although this difference
was not signiﬁcant. TheMIC90 of teicoplanin was higher for wild-typeMRSA (1.5 mg/L vs. 1 mg/L), but theMIC of vancomycin was not different
between the two groups. The 30-day mortality of MRSAwith a high MIC of teicoplanin (≥1.5 mg/L) was higher than that of strains with a lower
MIC (≤0.75 mg/L) (6/10 vs. 6/33, p 0.017). Mutation of the psm-mec promoter contributes to virulence of SCCmec-II MRSA, and the product of
psm-mec may determine the clinical characteristics of bacteraemia caused by SCCmec-II MRSA, but it does not affect mortality.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) has rapidly
spread in healthcare settings worldwide [1]. Community-asso-
ciated (CA) MRSA, the USA300 (SCCmec-IV) and USA400
(SCCmec-V) strains, has been observed in especially North
America over the last decade [2]. The virulence of CA-MRSA
is higher than that of hospital-associated (HA)-MRSA, possibly
because of the production of Panton-Valentine leukocidine
(PVL) [3]. However, there is controversy as to whether the
role of PVL affects disease severity and clinical outcome in
MRSA infection [4–6].
Recently, Wang et al. [7] found novel cytolytic peptides to
be the alpha-type phenol-soluble modulins (PSMs), which are
encoded in an operon present in all sequenced S. aureus
strains. PSMas consist of 20–25 amino acids and contribute to
evasion of the innate immune system by MRSA [7]. Production
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of PSMas is elevated in the most prevalent CA-MRSA strains,
and PSMas contribute to CA-MRSA virulence in vivo [7].
Recent reports suggest that the transcription and translation
products of psm-mec, which is located in the mobile genetic
elements SCCmec-II and -III in HA-MRSA, suppress the
production of PSMas [8,9].
Limited surveillance data on the genetic characteristics of
MRSA are available in Japan; the NY/Japan clone (SCCmec-II)
was predominantly clinically isolated. SCCmec-IV MRSA was
detected in only 4–20% of samples, and these strains did not
contain the lukS/F-PV gene [10,11]. Thus, the characteristics of
CA-MRSA strains in Japan are different from those of strains
reported in other countries.
Mutations in the psm-mec promoter found in HA-MRSA
(SCCmec-II) attenuated the transcription of psm-mec. These
strains showed increased expression of PSMas to levels
observed in the USA300 and USA400 strains [9]. We
hypothesized that PSMas may be important in determining
the manifestation and severity of invasive MRSA infections.
Our aim in this study was to examine whether SCCmec-II
MRSA strains with mutations in the psm-mec promoter, which
produce high amounts of PSMas, are associated with clinical
characteristics and outcome in bacteraemic patients.
Patients and Methods
Patients and study design
In total, 72 patients with MRSA bacteraemia were recruited
retrospectively from March 2009 to December 2011 at
Tohoku University Hospital, a 1300-bed tertiary-care teaching
hospital in Japan. Bacteraemia was deﬁned based on positive
blood culture with systemic manifestation of infection. We
excluded patients who (i) presented other pathogens in the
blood culture during one MRSA bacteraemia episode; (ii) were
dead within 24 h after the blood culture was obtained; and (iii)
were under 18 years of age. Thus, 52 patients were ultimately
enrolled.
The following data were collected from each patient’s
electric medical record: age, sex, hospitalization data, housing,
co-morbidities, infection site, risk factors for MRSA infection,
including recent surgery, wounds and insertion of catheters,
and site of MRSA infection. Complications of MRSA bacter-
aemia were evaluated using radiological records such as
computed tomography in addition to surgical pathology and
additional culture results. The outcomes studied included
30-day mortality and length of hospital stay (LOHS). Data
collection was approved by the Ethics Committees of Tohoku
University.
Microbiological molecular analysis
Methicillin-resistant Staphylococcus aureus was conﬁrmed by
mecA gene carriage, and the presence of the lukS/F-PV gene was
investigated by polymerase chain reaction (PCR) [12]. Type of
SCCmec was determined by using SCCmec-II speciﬁc primers
[12] or the class of the mec and the ccr gene complex [13].
DNA fragments including the psm-mec were sequenced by
using primers as previously reported [8]. Type of polymorphic
region of the protein A gene (spa) was determined by
sequenced spa PCR [14]. We present the primers used in this
study in Table S1.
Measurement of PSMs
The amount of PSMas was measured as previously described
[9]. Brieﬂy, MRSA culture supernatants were evaporated and
the remaining solid was dissolved in 40% acetonitrile. The
supernatants remaining after subsequent centrifugation were
evaporated, and the evaporated products were dissolved in
water and subjected to reversed-phase high-performance
liquid chromatography (HPLC). d-hemolysin (Hld) and PSMa1
were not separated in this system.
Bioﬁlm formation assay
Methicillin-resistant Staphylococcus aureus was cultured in
tryptic soy broth containing 0.25% glucose in 96-well polysty-
rene plates for 3 days at 37°C. Cells attached to the plate
were stained with safranin; staining was measured according to
the absorbance at 490 nm.
Expression of AgrA
Protein of AgrA was obtained through sodium dodecyl
sulphate (SDS)-polyacrylamide gel. Expression of AgrA was
performed by western blotting assay as previously described
[9]. The band intensity was measured by densitometry
scanning (Image J 1.45 s, NIH).
Antimicrobial susceptibility
The minimal inhibitory concentration (MIC) of vancomycin and
teicoplanin was determined by the E-test (range 0.016–
256 mg/L; bioMerieux, Lyon, France). The MIC breakpoint
for vancomycin and teicoplanin resistance was >2 mg/L
according to EUCAST [15].
Statistical analysis
Descriptive statistics, such as means, standard deviations,
frequencies and percentages, were collected. The chi-squared
test, Fisher’s exact test and unpaired t-test were conducted
using Graphpad prism 5 (GraphPad Software, La Jolla, CA,
USA). p < 0.05 was considered statistically signiﬁcant.
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Results
Molecular characteristics of MRSA isolated from blood
cultures
Figure 1 shows the gene sequencing data; 10 of 52 MRSA
isolates (19.2%) had a point mutation (-7T>C) in the
psm-mec promoter (Table 1). Fifty-one out of 52 (98.1%)
MRSA isolates were classiﬁed as SCCmec-II, but one MRSA
isolate without psm-mec gene was classiﬁed as SCCmec-IV.
None of the MRSA isolates carried the LukS/F-PV gene. Forty
out of 51 (78.4%) SCCmec-II MRSA isolates were classiﬁed
as spa type t002: 31 (76%) of intact psm-mec MRSA; nine
(90%) of a mutated psm-mec promoter MRSA. These data
indicated that MRSA strains with a mutated psm-mec
promoter and intact psm-mec have a closely related genetic
background.
Production of PSMas, bioﬁlm formation and AgrA expression
by MRSA isolates
PSMa3 production by MRSA isolates with a mutated psm-mec
promoter was ﬁve-fold higher than that by MRSA isolates with
intact psm-mec (p 0.023) and was equal to that by the
SCCmec-IV MRSA isolate that did not contain psm-mec
(Fig. 2b). However, there was no difference in the expression
of PSMa1 + hld between mutant and wild-type MRSA
(Fig. 2a). Mutant MRSA formed signiﬁcantly less bioﬁlm than
wild-type strains (p 0.0062), and the MRSA that did not
contain psm-mec also showed decreased bioﬁlm formation
(Fig. 2c).
The accessory gene regulator (agr) system represents a
prototype of quorum-sensing regulators, which has been
recognized as a pivotal regulator of virulence factor expression
[16]. AgrA binds to the psm promoter regions directly and
regulates PSMas production [17]. However, psm-mec-RNA
inhibits translation of the agrA gene by speciﬁc binding to agrA
mRNA [9]. In our study, the AgrA expression of both no
psm-mec and mutant MRSA was higher than that of wild-type
MRSA (Fig. 2d).
Comparison of clinical characteristics and outcome between
mutant and wild-type MRSA
Among the 51 SCCmec-II MRSA isolates, we did not detect any
difference in age, sex, underlying disease or hospital settings
between mutant and wild-type MRSA strains. Hospital-associ-
ated community onset (HACO) MRSA bacteraemia occurred
more frequently in patients infected by mutant MRSA than in
those infected by wild-type strains (4/10 vs. 4/41, p 0.038;
Table 2).
In total, 33 (63.5%) patients with MRSA bacteraemia were
diagnosed as having catheter-related blood stream infection
(CRBSI), and intact MRSA isolates were more frequently found
in patients with CRBSI (30/41 vs. 3/10, p 0.0028). However,
mutant MRSA was obtained more frequently in cases of
pneumonia with MRSA bacteraemia (2/10 vs. 0/41, p 0.035).
Additionally, 7/51 (13.5%) patients had the complication of
abscess formation, and mutant MRSA was associated with
abscess formation more frequently than wild-type MRSA (4/10
vs. 3/41, p 0.035; Table 2).
In total, 14/51 (27.5%) patients were dead within 30 days
of MRSA bacteraemia. The 30-day mortality rate was lower
in MRSA bacteraemia caused by mutant MRSA than in
bacteraemia caused by the wild-type strains, but the
difference was not signiﬁcant (1/10 vs. 13/41, p 0.25).
However, the patients’ LOHS for bacteraemia caused by
mutant MRSA was longer than that for bacteraemia caused
by wild-type strains (57 days vs. 37 days, p 0.4062), although
this difference also did not reach statistical signiﬁcance.
+1
Mutation in the psm-mec promoter (-7T>C) psm-mec ORF
5’- TTGTTTGATATTATACTTAATGTATCTTAAATAGAAAGAGGGTATGCATATGGATTTCACTGGTGTTATTACAAGCATTATTGATTTAAT -3’
3’- AACAAACTATAATATGAATTACATAGAATTTATCTTTCTCCCATACGTATACCTAAAGTGACCACAATAATGTTCGTAATAACTAAATTA -5’
5’- CAAGACTTGCATTCAGGCTTTCGGTTAATTTTTTCAACTA -3’
3’- GTTCTGAACGTAAGTCCGAAAGCCAATTAAAAAAGTTGAT -5’
FIG. 1. Nucleotide sequence of the psm-mec open reading frame (ORF) in SCCmec-II. The nucleotide sequence of the psm-mec ORF and its
promoter is shown [8, 30]. The psm-mecORF (grey) is encoded from left to right. Black bold nucleotide A indicates the transcription start site (+1) of
the psm-mec ORF. Underlined nucleotides (TATACT) indicate the -10 region of the psm-mec promoter; a -7T>C point mutation in the promoter
region was found in this study.
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Difference between MIC values of vancomycin and
teicoplanin in SCCmec-II MRSA
Methicillin-resistant Staphylococcus aureus bacteraemia and
pneumonia caused by high-MIC glycopeptides (vancomycin
and teicoplanin) are associated with an unfavourable outcome
[18–20]. We did not detect any difference in the MIC50 and
MIC90 values of vancomycin between mutant and wild-type
MRSA strains (MIC50, 2 mg/L vs. 2 mg/L; MIC90, 1.5 mg/L vs.
1.5 mg/L). However, the MIC50 and MIC90 values of teicopl-
anin in MRSA were lower than those in wild-type strains
(MIC50, 0.75 mg/L vs. 1 mg/L; MIC 90, 1 mg/L vs. 1.5 mg/L;
Fig. 3a).
In our study, the 30-day mortality rate did not depend on
the MIC of vancomycin; however, MRSA isolates with a high
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FIG. 2. Mutation of the psm-mec promoter in SCCmec-II MRSA strains increases the amount of extracellular PSMs and decreases bioﬁlm formation.
The amount of PSMa1 + Hld (a) and PSMa3 (b) in each clinically isolated MRSA strain (psm-mec-absent MRSA (n = 1), mutated psm-mec promoter
MRSA (n = 10), wild-type psm-mec promoter MRSA (n = 41)) was measured by HPLC. (c) Bioﬁlm formation of each MRSA strain onto polystyrene
microplates was examined. (a–c) Mean  standard deviation (SD) from three independent experiments is presented. Statistical analysis was
performed using the Mann–Whitney test. (d) Cell extra production of MRSA culture was subjected to western blotting by anti-AgrA IgG and band
intensities of AgrA were measured. Data analysis was presented to calculate the relative ratio against AgrA expression of wild-type psm-mec
promoter MRSA. Means and SD from three independent experiments are presented. Statistical analysis was performed using the Student t-test.
TABLE 1. Molecular characteristics of 52 MRSA strains from blood cultures
psm-mec gene
Number of
isolates
(n = 52)
SCCmec
type spa type
LukS/F-PVII IV t002 t242 t437 t045 t439 t539 t688 t1094 t8602 NT
Absence 1 1 1 0
The mutation in the
psm-mec promotor
(-7T>C)
10 10 9 1 0
Intact 41 41 31 4 1 1 1 1 1 1 0
NT, non-typable.
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MIC of teicoplanin (≥1.5 mg/L) (i.e. isolates with an intact
psm-mec gene) were associated with signiﬁcantly higher
mortality than isolates with low teicoplanin MIC (≤0.75 mg/
L) (6/10 vs. 6/33, p 0.017).
Discussion
CA-MRSA is suggested to secrete a high amount of toxins,
including PSMa, PVL and Hld. These toxins are involved in
evading and destroying host defences, and have been associ-
ated with skin infections, necrotizing pneumonia and abscess
formation in animal models [21]. However, the molecular
mechanism underlying the high virulence of CA-MRSA is not
fully understood in humans. PVL is not associated with
increased mortality from MRSA bacteraemia, and most cases
of MRSA infection are complicated with bacteraemia associ-
ated with skin and soft tissue infection [4,6]. In some
countries, PVL-positive strains are not present in many cases
of MRSA bacteraemia [22,23]. In this study, we did not
observe PVL-positive MRSA strains, and 98% of the MRSA
strains were classiﬁed as SCCmec-II. These data suggest that
factors other than PVL contribute to the pathogenesis of
MRSA in Japan.
PSMas and Hld had lytic activity against neutrophils [7].
However, it remains unclear whether these cytolytic toxins
contribute to the clinical characteristics and outcome of
human MRSA infections, as only one case report has
described the potential association of an SCCmec-II MRSA
strain with high PSMas and Hld with severe infection in Japan
[24]. In this study, 20% of MRSA isolates had a mutation
(-7T>C) in the psm-mec promoter, and these strains
produced a signiﬁcantly higher amount of PSMa3 than the
wild-type MRSA strains. PSMa3 has higher proinﬂammatory
and lysis activity compared with other PSMas and Hld [7].
Thus, a high amount of PSMa3 production may determine the
characteristics of MRSA infection. On the other hand,
wild-type MRSA isolates had signiﬁcantly higher bioﬁlm
formation than the mutant strains. These results suggest that
the wild-type psm-mec in SCCmec-II MRSA inhibits the
virulence properties that lead to invasive infections such as
pneumonia and abscess formation while promoting the
virulence properties associated with attachment to intrave-
nous catheters that lead to CRBSI.
CRBSI was more frequently associated with HA-MRSA
infection, but CA-MRSA was associated with a higher
proportion of pneumonia and deep-site abscesses with
bacteraemia [25–27]. In our study, mutant MRSA caused
infections other than CRBSI and was frequently associated
with pneumonia and abscess formation. However,
CA-MRSA was previously associated with lower mortality
or better outcomes than HA-MRSA [25,26,28], possibly
because the patients with CA-MRSA bacteraemia in these
studies were younger and had fewer co-morbidities. In our
study, there was no difference in age or co-morbidities
TABLE 2. Comparison of clinical characteristics and out-
come between SCCmec-II MRSA isolates with and without a
mutated psm-mec promoter
Mutant
MRSAa
(n = 10)
Wild-type
MRSAb
(n = 41) p value
Age (median, 25–75%) 71 (63.3–77.3) 72 (61.0–77.0) 0.869
>65 year 7 (64%) 31 (76%) 0.701
Male 8 (73%) 26 (63%) 0.463
Underlying condition, No. (%)
Cardiovascular disease 4 (40%) 13 (32%)
Malignancy (solid cancer) 2 (20%) 8 (20%)
Central nervous system
disease
1 (10%) 9 (22%)
Chronic renal failure 2 (20%) 7 (17%)
Diabetes mellitus 3 (30%) 6 (15%)
Autoimmune disease 2 (20%) 5 (12%)
Corticosteroid use 2 (20%) 5 (12%)
Digestive disease 0 (0%) 6 (15%)
Chronic respiratory disease 1 (10%) 3 (7%)
Chronic liver disease 0 (0%) 3 (7%)
Charlson co-morbity index
(mean, SD)
2.60 (2.17) 2.31 (1.88) 0.785
Hospital setting, No. (%)
Emergency room 1 (10%) 10 (24%) 0.424
Medical wards 5 (50%) 16 (39%) 0.722
Surgical wards 4 (40%) 15 (37%) 1.00
Site of acquisition, No. (%)
Community-associated
infectionc
0 (0%) 0 (0%)
Healthcare-associated
community onsetd
4 (40%) 4 (10%) 0.041*
Hospital onsete 6 (60%) 37 (90%)
Primary site of infection
CRBSI 3 (30%) 30 (73%) 0.0028*
CRBSI + multiple sites 1 (10%) 3 (10%) 0.330
Skin and soft tissue
infection
1 (10%) 3 (7%) 1.00
Surgical wound infection 0 (0%) 2 (5%) 1.00
Pneumonia 2 (20%) 0 (0%) 0.035*
IE 0 (0%) 1 (2%) 1.00
Vascular infection other
than IE
1 (10%) 0 (0%) 0.196
Intra-abdominal infection 1 (10%) 1 (2%) 0.357
Bone and joint 1 (10%) 1 (2%) 0.357
UTI 1 (10%) 0 (0%) 0.196
Sepsis (origin unknown) 0 (0%) 3 (7%) 1.00
Complication with MRSA bacteraemia
Abscess formation 4 (40%) 3 (7%) 0.035*
Deep vein thrombosis 0 (0%) 2 (5%) 1.00
Treatment
Vancomycin 6 (60%) 18 (44%) 0.49
Teicoplanin 2 (20%) 15 (37%) 0.46
Other agents of
anti-MRSA drugsf
2 (20%) 8 (20%) 1.00
Outcomes
30-day mortality 1 (10%) 13 (32%) 0.250
Length of hospital stay
(median, 25–75%)
57 (35.0–93.3) 37 (16.0–105.0) 0.406
MRSA, methicillin-resistant Staphylococcus aureus; CRBSI, catheter-related blood
stream infection; IE, infectious endocarditis; UTI, urinary tract infection.
aMutant MRSA: MRSA with a point mutation (-7T>C) in the psm-mec promoter.
bWild-type MRSA: MRSA intact in the psm-mec promoter.
cCommunity-associated infection: if the culture was obtained from an outpatient
or obtained ≤48 h after admission from a patient without documentation of a
healthcare risk factor.
dHealthcare-associated community onset (HACO): if the culture was obtained
from an outpatient or obtained ≤48 h after admission from a patient with a known
healthcare risk factor.
eHospital onset: if the ﬁrst positive blood culture was obtained ≥48 h after
admission.
fOther agents of anti-MRSA drugs were included in Linezolid and Arbekacin.
Data indicate the number (%) of patients, median  SD and median (25–75
percentile).
*p < 0.05.
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between patients with mutant MRSA and those with
wild-type MRSA, although the 30-day mortality rate for
bacteraemia caused by mutant MRSA was lower than that
for bacteremia caused by wild-type MRSA. The average
LOHS of bacteraemic patients with mutant MRSA was
longer than that of patients with wild-type MRSA. Taken
together, these ﬁndings suggested that the product of
psm-mec may be involved in clinical characteristics but does
not contribute to mortality.
In HACO MRSA isolates, SCCmec-II and -III strains were
found to be present together with SCCmec -IV and -V
strains [27,28]. In our study, eight of nine HACO MRSA
strains were classiﬁed as SCCmec-II, and 40% of the mutant
MRSA strains were isolated within 48 h of admission.
SCCmec-II mutant MRSA strains may cause MRSA bactera-
emia in patients with a history of exposure to commu-
nity-based medical care.
Methicillin-resistant Staphylococcus aureus bacteraemia and
higher vancomycin MIC values determined by the E-test have
a higher likelihood of mortality and treatment failure [18]. In
addition, CA-MRSA bacteraemia has a better outcome than
HA-MRSA bacteraemia because of the difference in vanco-
mycin MIC [29]. Teicoplanin is a glycopeptide alternative to
vancomycin and has been widely used in Europe and East
Asia. In previous studies, a higher MIC of teicoplanin
(>1.5 mg/L), as determined by the E-test, predicted unfa-
vourable outcome and higher mortality rate in bacteraemia
[19] and pneumonia [20], but these reports did not evaluate
the genetic background of the MRSA strains. In our study,
there was no difference in the MIC50 and MIC90 of
vancomycin for the two types of SCCmec-II MRSA, but the
MIC50 and MIC90 of teicoplanin for wild-type MRSA were
higher than those of the mutant MRSA. In addition, the
mortality rate was not associated with the MIC of vancomy-
cin, but the mortality of SCCmec-II MRSA with a higher
MIC of teicoplanin (≥1.5 mg/L) was signiﬁcantly higher than
that of SCCmec-II MRSA with a lower MIC of teicoplanin
(≤0.75 mg/L). These data indicate that the MIC of teicoplanin
may be a prognostic factor for bacteraemia caused by
SCCmec-II MRSA, and that the lower 30-day mortality of
bacteraemia associated with mutant MRSA may be related to
the lower MIC of teicoplanin.
This observational study has some limitations. First, this was
a single-centre study conducted in Japan with a small sample
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FIG. 3. MIC values of vancomycin and teicoplanin in SCCmec-II MRSA strains. Vancomycin and teicoplanin MIC values for SCCmec-II MRSA strains
(mutated psm-mec promoter MRSA (n = 10), wild-type psm-mec promoter MRSA (n = 41)) were evaluated by the E-test.
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size; therefore it may be possible that we could not ﬁnd a
signiﬁcant difference in clinical outcome between patients with
mutant MRSA and those with wild-type MRSA. Moreover, we
could not evaluate differences in clinical characteristics and
bacteraemia outcome between SCCmec-IV MRSA and mutant
SCCmec-II MRSA because the SCCmec-IV MRSA strain was
only isolated from a few samples. Second, Queck et al. found
that psm-mec has a positive effect on virulence of the
HA-MRSA strain MSA890, where the amount of the transla-
tional product of psm-mec was higher than that of other PSMs.
However, other strains in which the amount of the transla-
tional product of psm-mec was lower than that of other PSMs
did not recapitulate this effect in vitro and in vivo [30]. To
determine the extent to which our ﬁndings can be generalized,
further study is needed. Third, the clinical data in this
observational study were retrospectively collected and are
therefore subject to information bias. However, given that the
two groups were compared according to molecular typing and
antimicrobial susceptibility, this bias was likely to be inconse-
quential.
In conclusion, high production of PSMa3 by MRSA strains
containing mutated psm-mec was not associated with the
treatment outcome of MRSA bacteraemia but affected its
clinical characteristics. The difference in clinical impact
between these two different types of MRSA strains was
independent of teicoplanin MIC. Furthermore, the emergence
of the MRSA strain with mutated psm-mec and a high MIC of
teicoplanin indicates a need for vigorous strategies for clinical
management and infection control in both hospital and
community settings in Japan.
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